

The 2D-BioPAD Online Survey

What is 2D-BioPAD?

2D-BioPAD is a four-year research and development (R&D) project funded by the European Union's (EU) Horizon Europe Framework Programme for Research and Innovation 2021-2027 under Grant Agreement No. 101120706.

2D-BioPAD aims to introduce a fast and cost-effective, non-invasive, reliable, digitally, and graphene-enabled Point-of-Care (PoC) In-vitro Diagnostics (IVD) system for supporting early diagnosis and progression monitoring of Alzheimer's Disease (AD) directly at primary healthcare settings.

For more information, you can visit <https://2d-biopad.eu>.

What is the Online Survey about?

Based on ongoing desk research and interviews with field- and clinical experts (i.e., specialized/primary healthcare professionals, technical providers, and decision- and policy makers), the 2D-BioPAD team aims to better understand the potential of AD blood-derived (plasma) biomarkers for early detection and progression monitoring of AD, among other disease states.

Through the Online Survey the 2D-BioPAD team also aims to capture the current clinical practice both in primary- and specialized settings, including needs, challenges, barriers, and additional socioeconomic aspects that would hinder or enable the use of the 2D-BioPAD solution. Focus is also given to the potential use of promising PoC IVD, to inform the clinic-oriented development of the project requirements and solutions.

Who is the target audience?

Patients with subjective to mild cognitive impairment, caregivers, specialized/primary healthcare professionals, biomarker experts, decision- and policy makers.

Data privacy

The Online Survey will be anonymised, abiding by all European protocols and regulations.

Duration

The Online Survey will be conducted from the 15th of February until the 30th of April 2024.

The platform

The Online Survey will be conducted via the validated Greenlight Guru Clinical (GGC) platform, under the management of [EVNIA ApS](#).

Analysis

The main findings will be reported in the 2D-BioPAD's official report, whereas detailed scientific results may become available via scientific publications later in the year.



Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer's Disease

GA 101120706

Partners



Follow us

